Precigen Reports Third Quarter 2024 Financial Results and Business Updates
Portfolio Pulse from
Precigen, Inc. reported its Q3 2024 financial results and business updates, highlighting progress in its gene and cell therapy programs. The company completed a pre-BLA meeting with the FDA for PRGN-2012, initiated a confirmatory trial, and is preparing for a potential 2025 launch. Additionally, Precigen is preparing for an end of Phase 1b meeting for PRGN-3006 and presented promising preclinical data for PRGN-3008.
November 14, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen is advancing its gene and cell therapy pipeline with significant regulatory progress and upcoming product launches. The company is on track for a rolling BLA submission for PRGN-2012 and is preparing for a potential 2025 launch.
The completion of a pre-BLA meeting with the FDA and the initiation of a confirmatory trial for PRGN-2012 indicate strong regulatory progress, which is crucial for the potential 2025 launch. This progress is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100